The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Endocannabinoid System Targeted Therapeutics Market, 2020-2030

  • Lowest Price Guaranteed From USD 4,899

  • Published
    April 2020

  • Pages
    206

  • View Count
    4407

Example Insights

Endocannabinoid-System-Therapeutics-Market-Context Endocannabinoid-System-Therapeutics-Market-List-of-developer Endocannabinoid-System-Therapeutics-Market-Different-routes-thumb Endocannabinoid-System-Therapeutics-Market-Geographical-distribution-thumb
Endocannabinoid-System-Therapeutics-Market-Grant-analysis Endocannabinoid-System-Therapeutics-Market-Partnerships-and-collaborations-thumb Endocannabinoid-System-Therapeutics-Market-Mergers-and-acquisitions-thumb Endocannabinoid-System-Therapeutics-Market-Market-Forecast-thumb

 

Overview

Chronic conditions, such as arthritis, cancer, diabetes, and heart disease are known to affect approximately 133 million Americans, representing over 40% of the total US population. This number is projected to grow to 157 million by the end of 2020. In addition, nearly 20 million Americans are estimated to suffer from some form of neurological disorder. Such conditions are generally characterized by a variety of complex symptoms, such as seizures, chronic pain and sleep disorders, for which medical science has not yet been able to identify an underlying cause. Drugs that offer symptomatic relief are the only treatment option currently available for such conditions. Traditionally, the go-to option has been opioids. However, this class of drugs has a high propensity of being abused. Moreover, there is a substantial body of evidence that proves that the long-term use of opioids leads to addiction, and eventually results in secondary substance use disorders. Cannabis has been shown to have properties similar to that of opioids, offering relief from a wide range of clinical symptoms. On the other hand, owing to its strong psychoactive properties, it is widely used as a recreational drug. As a result, there are stringent policies regulating the use of this substance, worldwide. 

Over time, extensive R&D on the potential health benefits of cannabis, have enabled medical researchers to identify a number of pharmacologically active ingredients that offer clinical benefit, minus the addictive properties of the crude substance. Presently, cannabinoid derivatives, such as cannabidiol and cannabidivarin, have garnered the attention of the scientific community and are being investigated in mainstream clinical research initiatives. These molecules have been shown to modulate the endocannabinoid signaling system, primarily interacting with the CB1 and CB2 receptors. In fact, in 1985, the first synthetic cannabinoid drug, MARINOL®, was approved by the US FDA, for the treatment of nausea and vomiting, induced with chemotherapy. Recently, in 2018, EPIDIOLEX®, another cannabinoid derivative, was granted marketing authorization to be used to treat seizures associated with Lennox-Gastaut syndrome, or Dravet syndrome. Currently, there are several stakeholders in the pharmaceutical industry actively engaged in efforts to develop leads, derived from the Cannabis plant, as drugs to offer symptomatic relief across a diverse range of therapeutic areas. Of late, there has been substantial partnering activity in this field, as researchers / developers strive to forge strategic alliances, mostly to establish legitimate supply chains for raw material procurement, in order to support further research. Moreover, multiple start-ups, with backing from interested investors, have been established. As pioneers in this domain continue to achieve proof-of-concept, concerning the clinical benefits of this upcoming class of pharmacological molecules, we believe that this niche market is likely to witness substantial growth.

Scope of the Report

The “Endocannabinoid System Targeted Therapeutics Market, 2020-2030” report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of endocannabinoid system targeting drugs, over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes:

  • A detailed assessment of the current market landscape of endocannabinoid system targeted therapeutics, providing information on phase of development (clinical, preclinical, and discovery stage) of lead candidates, target therapeutic area (s), route of administration (oral, topical, sublingual, oromucosal, inhalation and others), dosing frequency (once daily, twice daily, thrice daily and others) and target receptor (CB1, CB2, TRPV-1 and others). Additionally, the chapter includes information on drug developer(s), including information on year of establishment, company size, and location of headquarters.
  • Elaborate profiles of prominent endocannabinoid system targeted therapeutics developers that are engaged in the development of at least four development programs. Each profile features a brief overview of the company, its financial information (if available), product portfolio and an informed future outlook.
  • An in-depth analysis of nearly 600 grants that have been awarded to research institutes engaged in endocannabinoid system targeted projects, in the period between 2016 and 2020 (till January), including analysis based on important parameters, such as year of grant award, amount awarded, administration institute centre, funding institute centre, support period, type of grant application, purpose of grant award, grant mechanism, responsible study section, prominent program officers, and type of recipient organizations. 
  • An analysis of the partnerships that have been established in the recent past, covering acquisitions, licensing agreements, product development and commercialization agreements, research agreements, clinical trial agreements, joint venture agreements and other relevant types of deals. 
  • A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2016-2020, based on parameters, such as year of acquisition, type of acquisition, geographical location of the acquirer and the acquired company, key value drivers, and financial details of the deal (if available). In addition, the chapter evaluates the deal multiples of acquisitions specifically focused on endocannabinoid system targeted therapeutics, analysing them based on a number of parameters, namely annual revenues, number of employees and experience of the acquired company. Moreover, it presents a schematic world map representation of the geographical distribution of this activity, highlighting inter- and intracontinental deals.
  • An insightful chessboard analysis highlighting the most popular drug development strategies / paths adopted by various drug developers (with clinical candidates) in order to progress their lead drug candidates.

One of the key objectives of the report was to estimate the existing market size and the future opportunity for endocannabinoid system targeted therapeutics, over the next decade. Based on multiple parameters, such as target patient population, likely adoption and the annual treatment cost, we have provided informed estimates on the evolution of endocannabinoid system targeted therapeutics market for the period 2020-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] key target receptors (CB1, CB2, and others) [B] different target therapeutic areas (autoimmune disorders, genetic disorders, neurological disorders and pain disorders) [C] routes of administration (oral and inhalation) and [D] key geographical regions (North America, Europe, Asia-Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.  

The opinions and insights presented in the report were also influenced by discussions held with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals (in alphabetical order):

  • Oludare Odumosu (Chief Executive Officer, Zelira Therapeutics US)
  • Andrea Small-Howard (Chief Scientific Officer, GB Sciences)
  • Steeve Néron (Chief Operating Officer, Tetra Bio-Pharma)
  • Stephen Dahmer (Chief Medical Officer, Vireo Health)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the state of the market for endocannabinoid system targeted therapeutics, in the short-midterm and long term.

Chapter 3 provides a general overview of endocannabinoid system, including information on the key target receptors involved, role of cannabis-based therapies and their historical evolution. The chapter lays emphasis on the different target therapeutic areas / affiliated symptoms that can be potentially treated with endocannabinoid system targeted therapeutics. It also includes a discussion on the regulations and need for legalization of cannabis, the various challenges related to this intervention and highlights its future perspectives.

Chapter 4 includes information on more than 180 cannabis-based development programs that are either approved or being developed across different stages (clinical and preclinical / discovery) for the treatment of various therapeutic areas. It features a comprehensive analysis of marketed / pipeline molecules, highlighting, phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, route of administration (oral, topical, sublingual, oromucosal, inhalation and others), target receptor(s) (CB1, CB2, TRPV-1 and others) and target therapeutic area (s). In addition, the chapter provides information on drug developer(s), highlighting year of their establishment, location of headquarters and employee strength.

Chapter 5 provides detailed profiles of the drug developers having multiple drug development programs in their portfolio. Each profile features a brief overview of the company, its financial information (if available), product portfolio, recent developments and an informed future outlook.

Chapter 6 provides an analysis of nearly 600 grants that were awarded to research institutes engaged in endocannabinoid system targeted therapeutics related projects, in the period between 2016 and 2020 (till January) based on the important parameters associated with grants, such as the year of grant award, amount awarded, administration institute center, funding institute center, support period, type of grant application, purpose of grant award, grant mechanism, responsible study section, prominent program officers, and type of recipient organizations. 

Chapter 7 features an elaborate analysis and discussion on the various collaborations and partnerships that have been inked amongst stakeholders in this domain, since 2016. It includes a brief description of various types of partnership models (namely acquisitions, licensing agreements, product development and commercialization agreements, research agreements, clinical trial agreements, joint venture agreements and other agreements) that have been adopted by stakeholders in this domain. 

Chapter 8 features a detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2016-2020, based on parameters, such as key value drivers, year of acquisition, type of acquisition, geographical location of the acquirer and the acquired company, and financial details of the deal (if available). In addition, the chapter evaluates the deal multiples of acquisitions specifically focused on endocannabinoid system targeted therapeutics, analyzing them based on a number of parameters, namely annual revenues, number of employees and the experience of the acquired company. Moreover, it presents a schematic world map representation of the geographical distribution of this activity, highlighting inter- and intracontinental deals.

Chapter 9 features an insightful chessboard analysis highlighting the most popular drug development strategies / paths adopted by various drug developers (with clinical candidates) engaged in this domain in order to accelerate the progress of their lead drug candidates.

Chapter 10 features a detailed market forecast analysis, highlighting the likely growth of endocannabinoid system targeted therapeutics till the year 2030. We have provided inputs on the likely distribution of the opportunity based on different target therapeutic area (autoimmune disorders, genetic disorders, neurological disorders and pain disorders), key target receptors (CB1, CB2, and others), routes of administration (oral and inhalation), and key geographical regions (North America, Europe, Asia-Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

Chapter 11 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it captures the evolutionary trends that are likely to determine the future of this segment of the endocannabinoid system targeted therapeutics industry.

Chapter 12 is a collection of interview transcripts of discussions held with key stakeholders in this market. In this chapter, we have presented a brief overview of the companies and details of our conversations held with Oludare Odumosu (Managing Director, Zelira Therapeutics US), Andrea Small-Howard (Chief Scientific Officer, GB Sciences), Steeve Néron (Chief Operating Officer, Tetra Bio-Pharma), Stephen Dahmer (Chief Medical Officer, Vireo Health).

Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 14 is an appendix, which contains a list of companies and organizations mentioned in this report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Neuropharmacology and Working Mechanism of the Endocannabinoid System
3.3. Potential Therapeutic Applications of Cannabinoids
3.4. Legal Aspects and Regulations
3.5. Existing Challenges
3.6. Future of Cannabinoid-based Therapies

4. MARKET LANDSCAPE: ENDOCANNABINOID SYSTEM TARGETED THERAPEUTICS
4.1. Chapter Overview

4.2. Drugs Targeting Endocannabinoid System: Marketed and Development Pipeline
4.3. Endocannabinoid System Targeted Therapeutics: Pipeline Analysis
4.3.1. Analysis by Phase of Development
4.3.2. Analysis by Target Therapeutic Area
4.3.3. Analysis by Route of Administration
4.3.4. Analysis by Dosing Frequency
4.3.5. Analysis by Target Receptor
4.3.6. Grid Analysis: Distribution by Phase of Development, Target Therapeutic Area and Target Receptor

4.4. Endocannabinoid System Targeted Therapeutics: List of Developers
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size and Geographical Location

5. COMPANY PROFILES
5.1. Chapter Overview
5.2. GW Pharmaceuticals
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Endocannabinoid Targeting Therapeutics Portfolio
5.2.3.1. Marketed / Clinical-stage Molecules
5.2.4. Recent Developments and Future Outlook

5.3. Corbus Pharmaceuticals
5.3.1. Company Overview
5.3.2. Endocannabinoid Targeting Therapeutics Portfolio
5.3.2.1. Marketed / Clinical-stage Molecules
5.3.2.2. Pre-Clinical-stage Molecules
5.3.3. Recent Developments and Future Outlook

5.4. Tilray
5.4.1. Company Overview
5.4.2. Financial Information
5.4.3. Endocannabinoid Targeting Therapeutics Portfolio
5.4.3.1. Marketed / Clinical-stage Molecules
5.4.4. Recent Developments and Future Outlook

5.5. Tetra Bio-Pharma
5.5.1. Company Overview
5.5.2. Endocannabinoid Targeting Therapeutics Portfolio
5.5.2.1. Marketed / Clinical-stage Molecules
5.5.3. Recent Developments and Future Outlook

5.6. Botanix Pharmaceuticals
5.6.1. Company Overview
5.6.2. Endocannabinoid Targeting Therapeutics Portfolio
5.6.2.1. Marketed / Clinical-stage Molecules
5.6.2.2. Pre-Clinical-stage Molecules
5.6.3. Recent Developments and Future Outlook
5.7. Kalytera Therapeutics
5.7.1. Company Overview
5.7.2. Endocannabinoid Targeting Therapeutics Portfolio
5.7.2.1. Marketed / Clinical-stage Molecules
5.7.2.2. Pre-Clinical-stage Molecules
5.7.3. Recent Developments and Future Outlook

5.8. Therapix Biosciences
5.8.1. Company Overview
5.8.2. Endocannabinoid Targeting Therapeutics Portfolio
5.8.2.1. Marketed / Clinical-stage Molecules
5.8.2.2. Pre-Clinical-stage Molecules
5.8.3. Recent Developments and Future Outlook

5.9. Avicanna
5.9.1. Company Overview
5.9.2. Financial Information
5.9.3. Endocannabinoid Targeting Therapeutics Portfolio
5.9.3.1. Marketed / Clinical-stage Molecules
5.9.3.2. Pre-Clinical-stage Molecules
5.9.4. Recent Developments and Future Outlook

5.10. GB Sciences
5.10.1. Company Overview
5.10.2. Financial Information
5.10.3. Endocannabinoid Targeting Therapeutics Portfolio
5.10.3.1. Pre-Clinical-stage Molecules
5.10.4. Recent Developments and Future Outlook

5.11. Echo Pharmaceuticals
5.11.1. Company Overview
5.11.2. Endocannabinoid Targeting Therapeutics Portfolio
5.11.2.1. Endocannabinoid Targeting Therapeutics Portfolio
5.11.2.2. Pre-Clinical-stage Molecules

6. ACADEMIC GRANTS ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. Endocannabinoid System Targeted Therapeutics: Academic Grant Analysis
6.3.1. Analysis by Year of Grant Award
6.3.2. Analysis by Amount Awarded
6.3.3. Analysis by Administering Institute Center
6.3.4. Analysis by Funding Institute Center
6.3.5. Analysis by Support Period
6.3.6. Analysis by Funding Institute Center and Support Period
6.3.7. Analysis by Type of Grant Application
6.3.8. Analysis by Purpose of Grant Award
6.3.9. Analysis by Activity Code
6.3.10. Word Cloud Analysis: Emerging Focus Areas
6.3.11. Analysis by Study Section Involved
6.3.12. Popular NIH Departments: Analysis by Number of Grants
6.3.13. Analysis by Types of Recipient Organizations
6.3.14. Prominent Program Officers: Analysis by Number of Grants
6.3.15. Popular Recipient Organizations: Analysis by Number of Grants
6.3.16. Regional Distribution of Recipient Organizations

7. PARTNERSHIPS AND COLLABORATIONS
7.1. Chapter Overview
7.2. Partnership Models
7.3. Endocannabinoid Targeted Therapeutics: List of Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Type of Partnership and Type of Partner
7.3.4. Analysis by Year of Partnership and Type of Partner
7.3.5. Most Active Players: Analysis by Number of Partnerships
7.3.6. Regional Analysis
7.3.7. Intercontinental and Intracontinental Agreements

8. MERGERS AND ACQUISITIONS
8.1. Chapter Overview
8.2. Merger and Acquisition Models
8.3. Endocannabinoid Targeted Therapeutics: Mergers and Acquisitions
8.3.1. Analysis by Year of Mergers and Acquisitions
8.3.2. Analysis by Type of Mergers and Acquisitions
8.3.3. Continent-wise Distribution
8.3.4. Country-wise Distribution
8.3.5. Analysis by Key Value Drivers
8.3.6. Analysis by Key Value Drivers and Year of Acquisition
8.3.7. Key Value Drivers
8.3.8. Valuation Analysis: Acquisition Deal Multiples

9. DRUG DEVELOPMENT STRATEGY ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Strategies Adopted for Late-Stage Drug Candidates
9.3.1. EPIDIOLEX
9.3.2. CannEpil
9.3.3. Lenabasum
9.3.4. CAUMZ
9.3.5. CBD Oil
9.4. Concluding Remarks

10. MARKET FORECAST AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Global Endocannabinoid Targeted Therapeutics Market, 2020-2030
10.4. Global Endocannabinoid Targeted Therapeutics Market: Individual Product Sales Forecasts
10.4.1. EPIDIOLEX (GW Pharmaceuticals)
10.4.1.1. Target Patient Population
10.4.1.2. Sales Forecast

10.4.2. CannEpil (MGC Pharmaceuticals)
10.4.2.1. Target Patient Population
10.4.2.2. Sales Forecast
10.4.3. GWP42003-P (GW Pharmaceuticals)
10.4.3.1. Target Patient Population
10.4.3.2. Sales Forecast

10.4.4. Lenabasum (Corbus Pharmaceuticals)
10.4.4.1. Target Patient Population
10.4.4.2. Sales Forecast

10.4.5. PPP011 (Tetra Bio-Pharma)
10.4.5.1. Target Patient Population
10.4.5.2. Sales Forecast

10.5. Global Endocannabinoid System Targeted Therapeutics Market: Distribution by Target Receptor, 2025 and 2030
10.5.1. Global Endocannabinoid System Targeted Therapeutics Market for CB1 and CB2 Receptor Targeted Therapies, 2021-2030
10.5.2. Global Endocannabinoid System Targeted Therapeutics Market for CB2 Receptor Targeted Therapies, 2022-2030
10.5.3. Global Endocannabinoid System Targeted Therapeutics Market for Other Receptor Targeted Therapies, 2022-2030
10.6. Global Endocannabinoid System Targeted Therapeutics Market: Distribution by Region, 2025 and 2030
10.6.1. Endocannabinoid System Targeted Therapeutics Market in the US, 2020-2030
10.6.2. Endocannabinoid System Targeted Therapeutics Market in the UK, 2020-2030
10.6.3. Endocannabinoid System Targeted Therapeutics Market in Germany, 2020-2030
10.6.4. Endocannabinoid System Targeted Therapeutics Market in France, 2020-2030
10.6.5. Endocannabinoid System Targeted Therapeutics Market in Italy, 2020-2030
10.6.6. Endocannabinoid System Targeted Therapeutics Market in Spain, 2020-2030
10.6.7. Endocannabinoid System Targeted Therapeutics Market in Japan, 2022-2030
10.6.8. Endocannabinoid System Targeted Therapeutics Market in Australia, 2020-2030

10.7. Global Endocannabinoid System Targeted Therapeutics Market: Distribution by Target Therapeutic Area, 2025 and 2030
10.7.1. Global Endocannabinoid System Targeted Therapeutics Market for Autoimmune Diseases, 2022-2030
10.7.2. Global Endocannabinoid System Targeted Therapeutics Market for Cancer, 2022-2030
10.7.3. Global Endocannabinoid System Targeted Therapeutics Market for Inflammatory Diseases, 2022-2030
10.7.4. Global Endocannabinoid System Targeted Therapeutics Market for Genetic Disorders, 2021-2030
10.7.5. Global Endocannabinoid System Targeted Therapeutics Market for Neurological Disorders, 2020-2030

10.8. Global Endocannabinoid System Targeted Therapeutics Market: Distribution by Route of Administration, 2025 and 2030
10.8.1. Global Endocannabinoid System Targeted Therapeutics Market for Oral Therapies, 2020-2030
10.8.5. Global Endocannabinoid System Targeted Therapeutics Market for Inhalation Therapies, 2022-2030

11. CONCLUDING REMARKS

12. EXECUTIVE INSIGHTS
12.1. Chapter Overview
12.2 Zelira Therapeutics US
12.2.1. Company Snapshot
12.2.2. Interview Transcript: Oludare Odumosu, Chief Executive Officer

12.3. GB Sciences
12.3.1. Company Snapshot
12.3.2. Interview Transcript: Andrea Small-Howard, Chief Scientific Officer

12.4. Tetra Bio-Pharma
12.4.1. Company Snapshot
12.4.2. Interview Transcript: Steeve Néron, Chief Operating Officer

12.5 Vireo Health
12.5.1. Company Snapshot
12.5.2. Interview Transcript: Stephen Dahmer, Chief Medical Officer

13. APPENDIX 1: TABULATED DATA

14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Medical Cannabis: Historical Timeline
Figure 3.2 Cannabinoid Receptors: Distribution in Human Body 
Figure 3.3 Endocannabinoids: Potential Therapeutic Areas
Figure 3.4 Medical Cannabis: Legal Landscape
Figure 3.5 Cannabis Legalization: Existing Challenges
Figure 3.6 Cannabis: Need for Legalization
Figure 4.1 Endocannabinoid System Targeted Therapeutics: Distribution by Phase of Development
Figure 4.2 Endocannabinoid System Targeted Therapeutics: Distribution by Target Therapeutic Area
Figure 4.3 Endocannabinoid System Targeted Therapeutics: Distribution by Target Therapeutic Area and Phase of Development
Figure 4.4 Endocannabinoid System Targeted Therapeutics: Distribution by Route of Administration
Figure 4.5 Endocannabinoid System Targeted Therapeutics: Distribution by Dosing Frequency
Figure 4.6 Endocannabinoid System Targeted Therapeutics: Distribution by Target Receptor
Figure 4.7 Endocannabinoid System Targeted Therapeutics: Distribution by Phase of Development, Target Therapeutic Area and Target Receptor
Figure 4.8 Endocannabinoid System Targeted Therapeutics: Distribution by Year of Establishment
Figure 4.9 Leading Developers: Distribution by Number of Therapies for Targeting Endocannabinoid System
Figure 4.10 Endocannabinoid System Targeted Therapeutics: Distribution Company Size and Geographical Location
Figure 4.11 World Map Representation: Distribution by Geography
Figure 5.1 GW Pharmaceuticals: Annual Revenues, 2015-2019 (USD Million)
Figure 5.2 Tilray: Annual Revenues, 2016- 2019 (USD Million)
Figure 5.3 Avicanna: Annual Revenues, 2017- 9M 2019 (USD Million)
Figure 5.4 GB Sciences: Annual Revenues, 2018- 2019 (USD Million)
Figure 6.1 Grant Analysis: Cumulative Trend by Year of Award, 2016-2020
Figure 6.2 Grant Analysis: Cumulative Distribution by Amount Awarded, 2016-2019 (USD Million)
Figure 6.3 Grant Analysis: Distribution by Administering Institute Center
Figure 6.4 Grant Analysis: Distribution by Funding Institute Center
Figure 6.5 Grant Analysis: Distribution by Support Period
Figure 6.6 Grant Analysis: Distribution by Funding Institute Center and Support Period
Figure 6.7 Grant Analysis: Distribution by Type of Grant Application
Figure 6.8 Grant Analysis: Distribution by Purpose of Grant Award
Figure 6.9 Grant Analysis: Distribution by Activity Code
Figure 6.10 Word Cloud Analysis: Emerging Focus Areas
Figure 6.11 Grant Analysis: Distribution by Study Section Involved
Figure 6.12 Popular NIH Departments: Distribution by Number of Grants
Figure 6.13 Grant Analysis: Distribution by Type of Recipient Organization
Figure 6.14 Grant Analysis: Prominent Program Officers
Figure 6.15 Popular Recipient Organizations: Distribution by Number of Grants
Figure 6.16 Grant Analysis: Regional Distribution of Recipient Organizations
Figure 7.1. Partnerships and Collaborations: Cumulative Trend by Year, 2016-2020
Figure 7.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 7.3. Partnerships and Collaborations: Distribution by Year and Type of Partnership (2016-2020)
Figure 7.4. Partnerships and Collaborations: Analysis by Year of Partnership and Type of Partner
Figure 7.5. Partnerships and Collaborations: Analysis by Type of Partnership and Type of Partner
Figure 7.6. Partnerships and Collaborations: Most Active Players
Figure 7.7. Partnership and Collaborations: Regional Distribution
Figure 7.8. Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 8.1 Mergers and Acquisitions: Cumulative Year-Wise Trend, 2016-2020
Figure 8.2 Mergers and Acquisitions: Distribution by Type of Agreements (2016-2020) 
Figure 8.3 Mergers and Acquisitions: Distribution by Year and Type of Agreements (2016-2020)
Figure 8.4 Mergers and Acquisitions: Continent-wise Distribution
Figure 8.5 Mergers and Acquisitions: Intercontinental and Intracontinental Agreements
Figure 8.6 Mergers and Acquisitions: Country-wise Distribution
Figure 8.7 Acquisitions: Distribution by Key Value Drivers
Figure 8.8 Acquisitions: Distribution by Key Value Drivers and Year of Acquisition (2016-2020)
Figure 9.1 Strategies Adopted by Late-Stage Drug Candidates
Figure 9.2 Strategies Adopted for EPIDIOLEX
Figure 9.3 Strategies Adopted for CannEpil
Figure 9.4 Strategies Adopted for Lenabasum
Figure 9.5 Strategies Adopted for CAUMZ
Figure 9.6 Strategies Adopted for CBD Oil
Figure 9.7 Endocannabinoid System Targeting Drug Developers: Popular Development Strategies
Figure 9.8 Drug Development Strategy: Preferred Paths to Market
Figure 10. 1 Global Endocannabinoid System Targeted Therapeutics Market, 2020-2030 (USD Million)
Figure 10. 2 Epidiolex Sales Forecast, 2020-2030 (USD Million)
Figure 10. 3 CannEpil Sales Forecast, 2020-2030 (USD Million)
Figure 10.4 GWP42003-P Sales Forecast, 2021-2030 (USD Million)
Figure 10.5 Lenabasum Sales Forecast, 2022-2030 (USD Million)
Figure 10.6 PPP011 Sales Forecast, 2022-2030 (USD Million)
Figure 10. 6 PPP011 (Caumz): Target Patient Population
Figure 10.7 Global Endocannabinoid System Targeted Therapeutics Market: Distribution by Target Receptor, 2025 and 2030 (USD Million)
Figure 10.8 Global Endocannabinoid System Targeted Therapeutics Market for CB1 and CB2 Receptor Targeted Therapies, 2021-2030 (USD Million)
Figure 10.9 Global Endocannabinoid System Targeted Therapeutics Market for CB2 Receptor Targeted Therapies, 2022-2030 (USD Million)
Figure 10.10 Global Endocannabinoid System Targeted Therapeutics Market for Other Receptor Targeted Therapies, 2022-2030 (USD Million)
Figure 10. 11 Global Endocannabinoid System Targeted Therapeutics Market: Distribution by Region, 2025 and 2030 (USD Million)
Figure 10. 12 Endocannabinoid System Targeted Therapeutics Market in the US, 2020-2030 (USD Million)
Figure 10. 13 Endocannabinoid System Targeted Therapeutics Market in the UK, 2020-2030 (USD Million)
Figure 10. 14 Endocannabinoid System Targeted Therapeutics Market in Germany, 2020-2030 (USD Million)
Figure 10. 15 Endocannabinoid System Targeted Therapeutics Market in France, 2020-2030 (USD Million)
Figure 10. 16 Endocannabinoid System Targeted Therapeutics Market in Italy, 2020-2030 (USD Million)
Figure 10. 17 Endocannabinoid System Targeted Therapeutics Market in Spain, 2020-2030 (USD Million)
Figure 10. 18 Endocannabinoid System Targeted Therapeutics Market in Japan, 2022-2030 (USD Million)
Figure 10. 19 Endocannabinoid System Targeted Therapeutics Market in Australia, 2020-2030 (USD Million)
Figure 10. 20 Global Endocannabinoid System Targeted Therapeutics Market: Distribution by Target Therapeutic Area, 2025 and 2030 (USD Million)
Figure 10. 21 Global Endocannabinoid System Targeted Therapeutics Market for Autoimmune Diseases, 2020-2030 (USD Million)
Figure 10. 22 Global Endocannabinoid System Targeted Therapeutics Market for Cancer, 2020-2030 (USD Million)
Figure 10. 23 Global Endocannabinoid System Targeted Therapeutics Market for Inflammatory Diseases, 2020-2030 (USD Million)
Figure 10. 24 Global Endocannabinoid System Targeted Therapeutics Market for Genetic Disorders, 2020-2030 (USD Million)
Figure 10.25 Global Endocannabinoid System Targeted Therapeutics Market for Neurological Disorders, 2020-2030 (USD Million)
Figure 10. 26 Global Endocannabinoid System Targeted Therapeutics Market: Distribution by Route of Administration, 2025 and 2030 (USD Million)
Figure 10. 27 Global Endocannabinoid System Targeted Therapeutics Market for Oral Therapies, 2020-2030 (USD Million)
Figure 10.28 Global Endocannabinoid System Targeted Therapeutics Market for Inhalation Therapies, 2022-2030 (USD Million)

List Of Tables

Table 4.1 Drugs Targeting Endocannabinoid System: Marketed and Development Pipeline
Table 4.2 Endocannabinoid System Targeted Therapeutics: List of Therapy Developers
Table 5.1 Endocannabinoid Targeting Therapeutics: List of Profiled Companies
Table 5.2 GW Pharmaceuticals: Company Snapshot
Table 5.3 Drug Profile: Marketed /  Clinical-stage Candidates
Table 5.4 GW Pharmaceuticals: Recent Developments and Future Outlook
Table 5.5 Corbus Pharmaceuticals: Company Snapshot
Table 5.6 Drug Profile: Marketed / Clinical-stage Candidates
Table 5.7 Drug Profile: Pre-clinical-stage Candidates
Table 5.8 Corbus Pharmaceuticals: Recent Developments and Future Outlook
Table 5.9 Tilray: Company Snapshot
Table 5.10 Drug Profile: Marketed / Clinical-stage Candidates
Table 5.11 Tilray: Recent Developments and Future Outlook
Table 5.12 Tetra Bio-Pharma: Company Snapshot
Table 5.13 Drug Profile: Marketed / Clinical-stage Candidates
Table 5.14 Tetra Bio-Pharma: Future Outlook
Table 5.15 Botanix Pharmaceuticals: Company Snapshot
Table 5.16 Drug Profile: Marketed / Clinical-stage Candidates
Table 5.17 Drug Profile: Preclinical-stage Candidates
Table 5.18 Botanix Pharmaceuticals: Future Outlook
Table 5.19 Kalytera Therapeutics: Company Snapshot
Table 5.20 Drug Profile: Marketed / Clinical-stage Candidates
Table 5.21 Drug Profile: Preclinical-stage Candidates
Table 5.22 Kalytera Therapeutics: Future Outlook
Table 5.23 Therapix Biosciences: Company Snapshot
Table 5.24 Drug Profile: Marketed / Clinical-stage Candidates
Table 5.25 Drug Profile: Pre-clinical-stage Candidates
Table 5.26 Therapix Biosciences: Future Outlook
Table 5.27 Avicanna: Company Snapshot
Table 5.28 Drug Profile: Marketed / Clinical-stage Candidates
Table 5.29 Drug Profile: Preclinical-stage Candidates
Table 5.30 Avicanna: Future Outlook
Table 5.31 GBSciences: Company Snapshot
Table 5.32 Drug Profile: Preclinical Candidates
Table 5.33 GBSciences: Future Outlook
Table 5.34 Echo Pharmaceuticals: Company Snapshot
Table 5.35 Drug Profile: Marketed / Clinical-stage Candidates
Table 5.36 Drug Profile: Preclinical-stage Candidates
Table 7.1 Endocannabinoid System Targeted Therapeutics: Partnerships and Collaborations, 2016-2020
Table 8.1 Endocannabinoid System Targeted Therapeutics: List of Mergers and Acquisitions, 2016-2020
Table 8.2 Acquisitions: Key Value Drivers
Table 10.1 Endocannabinoid System Targeted Therapeutics: List of Forecasted Candidates
Table 10.2 Epidiolex: Target Patient Population (Million)
Table 10.3 CannEpil: Target Patient Population (Million)
Table 10.4 GWP42003-P: Target Patient Population (Million)
Table 10.5 Lenabasum: Target Patient Population (Million)
Table 10.6 PPP011: Target Patient Population (Million)
Table 11.1 Endocannabinoid System Targeted Therapeutics: Summary of the Competitive Insights
Table 12.1 Echo Pharmaceuticals: Key Highlights
Table 12.2 GB Sciences: Key Highlights
Table 12.3 iX Biopharma: Key Highlights
Table 12.4 Tetra Bio-Pharma: Key Highlights
Table 12.5 Vireo Health: Key Highlights
Table 12.6 Zelira Therapeutics: Key Highlights
Table 13.1 Endocannabinoid System Targeted Therapeutics: Distribution by Phase of Development
Table 13.2 Endocannabinoid System Targeted Therapeutics: Distribution by Target Therapeutic Area
Table 13.3 Endocannabinoid System Targeted Therapeutics: Distribution by Route of Administration
Table 13.4 Endocannabinoid System Targeted Therapeutics: Distribution by Dosing Frequency
Table 13.5 Endocannabinoid System Targeted Therapeutics: Distribution by Target Receptor
Table 13.6 Endocannabinoid System Targeted Therapeutics Developers: Distribution by Year of Establishment
Table 13.7 Endocannabinoid System Targeted Therapeutics Developers: Analysis by Number of Pipeline Therapies
Table 13.8 Endocannabinoid System Targeted Therapeutics Developers: Distribution by Company Size and Geographical Location
Table 13.9 GW Pharmaceuticals: Annual Revenues, 2015-2019 (USD Million)
Table 13.10 Tilray: Annual Revenues, 2016-2019 (USD Million)
Table 13.11 Avicanna: Annual Revenues, 2017- 9M 2019 (USD Million)
Table 13.12 GB Sciences: Annual Revenues, 2018 and 2019 (USD Million)
Table 13.13 Grant Analysis: Cumulative Trend by Year of Award, 2016-2020
Table 13.14 Grant Analysis: Distribution by Funding Institute Center
Table 13.15 Grant Analysis: Distribution by Support Period
Table 13.16 Grant Analysis: Distribution by Type of Grant Application
Table 13.17 Grant Analysis: Distribution by Purpose of Grant Award
Table 13.18 Grant Analysis: Distribution by Activity Code
Table 13.19 Grant Analysis: Distribution by Study Section Involved
Table 13.20 Popular NIH Departments: Distribution by Number of Grants
Table 13.21 Grant Analysis: Distribution by Type of Recipient Organization
Table 13.22 Grant Analysis: Prominent Program Officers
Table 13.23 Popular Recipient Organizations: Distribution by Number of Grants
Table 13.24 Partnerships and Collaborations: Cumulative Trend by Year, 2016-2020
Table 13.25 Partnerships and Collaborations: Distribution by Type of Partnership
Table 13.26 Partnerships and Collaborations: Distribution by Year and Type of Partnership (2016-2020)
Table 13.27 Partnerships and Collaborations: Analysis by Year of Partnership and Type of Partner
Table 13.28 Partnerships and Collaborations: Partnerships and Collaborations: Analysis by Type of Partnership and Type of Partner
Table 13.29 Partnerships and Collaborations: Most Active Players
Table 13.30 Partnership and Collaborations: Regional Distribution
Table 13.31 Mergers and Acquisitions: Cumulative Year-Wise Trend (2016-2020)
Table 13.32 Mergers and Acquisitions: Distribution by Type of Agreement (2016-2020)
Table 13.33 Mergers and Acquisitions: Distribution by Year and Type of Agreement (2016-2020)
Table 13.34 Mergers and Acquisitions: Continent-wise Distribution
Table 13.35 Mergers and Acquisitions: Country-wise Distribution
Table 13.36 Acquisitions: Distribution by Key Value Drivers
Table 13.37 Acquisitions: Distribution by Key Value Drivers and Year of Acquisition (2016-2020)
Table 13.38 Global Endocannabinoid System Targeted Therapeutics Market, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.39 EPIDIOLEX: Sales Forecast, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.40 CannEpil: Sales Forecast, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.41 GWP42003-P: Sales Forecast, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.42 Lenabasum: Sales Forecast, 2022-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.43 PPP011: Sales Forecast, 2022-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.44 Global Endocannabinoid System Targeted Therapeutics Market: Distribution by Target Receptor, 2025 and 2030 (USD Million)
Table 13.45 Global Endocannabinoid System Targeted Therapeutics Market for CB1 and CB2 Receptor Targeted Therapies, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.46 Global Endocannabinoid System Targeted Therapeutics Market for CB2 Receptor Targeted Therapies, 2022-2030 (USD Million)
Table 13.47 Global Endocannabinoid System Targeted Therapeutics Market for Other Receptor Targeted Therapies, 2022-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.48 Global Endocannabinoid System Targeted Therapeutics Market: Distribution by Region, 2025 and 2030 (USD Million)
Table 13.49 Endocannabinoid System Targeted Therapeutics Market in the US, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.50 Endocannabinoid System Targeted Therapeutics Market in the UK, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.51 Endocannabinoid System Targeted Therapeutics Market in Germany, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.52 Endocannabinoid System Targeted Therapeutics Market in France, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.53 Endocannabinoid System Targeted Therapeutics Market in Italy, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.54 Endocannabinoid System Targeted Therapeutics Market in Spain, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.55 Endocannabinoid System Targeted Therapeutics Market in Japan, 2022-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.56 Endocannabinoid System Targeted Therapeutics Market in Australia, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.57 Endocannabinoid System Targeted Therapeutics Market: Distribution by Target Therapeutic Area, 2025 and 2030 (USD Million)
Table 13.58 Global Endocannabinoid System Targeted Therapeutics Market for Autoimmune Diseases, 2022-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.59 Global Endocannabinoid System Targeted Therapeutics Market for Cancer, 2022-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.60 Global Endocannabinoid System Targeted Therapeutics Market for Inflammatory Disorders, 2022-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.61 Global Endocannabinoid System Targeted Therapeutics Market for Genetic Disorders, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.62 Global Endocannabinoid System Targeted Therapeutics Market for Neurological Disorders, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.63 Global Endocannabinoid System Targeted Therapeutics Market: Distribution by Route of Administration, 2025 and 2030 (USD Million)
Table 13.64 Global Endocannabinoid System Targeted Therapeutics Market for Oral Therapies, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 13.65 Global Endocannabinoid System Targeted Therapeutics Market for Inhalation Therapies, 2022-2030: Conservative, Base and Optimistic Scenarios (USD Million)

Listed Companies

The following companies and organizations have been mentioned in the report:

  1. Abide Therapeutics
  2. Aelis Farma
  3. Agrima Botanicals
  4. Albany Molecular Research
  5. Alkem Laboratories
  6. Alliqua BioMedical
  7. Alternavida
  8. Altus Formulation
  9. Anandia Laboratories
  10. Aphios
  11. Aphria
  12. Aptus Clinical
  13. Arena Pharmaceuticals
  14. Artelo Biosciences
  15. Assuta Medical Centers
  16. Aurora Cannabis
  17. Authentic Brands Group
  18. Avicanna
  19. AXIM Biotechnologies
  20. Azevedos Indústria Farmacêutica
  21. Battelle
  22. Bausch Health
  23. BC Northern Lights
  24. Beckley Canopy Therapeutics
  25. Beetlebung Pharma
  26. Bird Rock Bio
  27. Botanix Pharmaceuticals
  28. C3 Cannabinoid Compound Company
  29. Canapalife Group
  30. Cannabics Pharmaceuticals
  31. Cannabis Science
  32. CannaKids
  33. Cannamedical Pharma
  34. Cannara Biotech
  35. CanniMed Therapeutics
  36. CannRx
  37. Canntab Therapeutics
  38. Canopy Growth
  39. CanvasRx
  40. Cara Therapeutics
  41. Catalent Pharma Solutions
  42. Champignon Brands
  43. Chemi Pharmaceutical
  44. Children’s Hospital of Philadelphia
  45. Ci Therapeutics
  46. Columbia University
  47. Constance Therapeutics
  48. Corbus Pharmaceuticals
  49. Cowen
  50. Cura Cannabis Solutions
  51. CURE Pharmaceutical
  52. Curtin University
  53. CV Sciences
  54. Dana-Farber Cancer Institute
  55. DayaCann
  56. Delivra
  57. ebbu
  58. Echo Pharmaceuticals
  59. Emerald Bioscience
  60. Emerald Clinics
  61. Emilia Cosmetics
  62. EnWave
  63. Ethicann Pharmaceuticals
  64. FDI Clinical Research
  65. FoliuMed
  66. Four20
  67. FSD Pharma
  68. FutureNeuro
  69. GB Sciences
  70. GE Healthcare
  71. GenCanna
  72. GlaxoSmithKline
  73. Greenbelt Greenhouse
  74. GreenLight Medicines
  75. GW Pharmaceuticals
  76. H2 Biopharma
  77. Harvest One Cannabis
  78. Health House
  79. Heavenly Rx
  80. Hempco Food and Fiber
  81. Hospital del Mar Medical Research Institute
  82. Impression Healthcare
  83. InMed Pharmaceuticals
  84. INSYS Therapeutics
  85. IntelGenx Technologies
  86. InterCure
  87. Inversago Pharma
  88. IsCann Group
  89. iX Biopharma
  90. Janssen Pharmaceuticals
  91. Jenrin Discovery
  92. Kaken Pharmaceutical
  93. Kalytera Therapeutics
  94. Kamada
  95. Kannalife Sciences
  96. Khiron Life Sciences
  97. KISS Industries
  98. Knop Laboratorios
  99. Larssen (acquired by Aurora Cannabis)
  100. LiveWell Cana da
  101. LSU AgCenter
  102. Lundbeck 
  103. LYPHE Group
  104. MAKScientific
  105. MannKind Corporation
  106. Medipure Pharmaceuticals
  107. MedLab Clinical
  108. MGC Pharmaceuticals
  109. Michigan State University
  110. Mitacs
  111. Montefiore Medical Center
  112. Nanomerics
  113. National and Kapodistrian University of Athens
  114. National Institute on Drug Abuse
  115. National Research Council of Canada
  116. Natura Naturals
  117. NEEKA Health Canada
  118. NEOMED Institute
  119. Neptune Technologies & Bioressources
  120. NettaGrowth International
  121. NHS Industries
  122. Niagara College
  123. Noramco
  124. Novartis
  125. Onegevity Health
  126. 126.   Oregon   01
  127. Ovensa
  128. OWC Pharmaceutical Research
  129. Panax Pharma
  130. Panag Pharma
  131. Parkinson's Foundation
  132. Pascal Biosciences
  133. Pedanios
  134. Peloton Pharmaceuticals
  135. Pharmascience
  136. Pharmaseed
  137. Pharmastrip
  138. PharmHouse
  139. Phivida
  140. Phytecs
  141. PhytoPain Pharma
  142. PhytoTech Therapeutics 
  143. Pompeu Fabra University
  144. Prairie Plant Systems
  145. Prismic Pharmaceuticals
  146. Privateer
  147. ProCaps Laboratories
  148. Pure Green
  149. Purisys
  150. QPS Netherlands
  151. Radient Technologies
  152. ReLeaf Europe
  153. Revive Therapeutics
  154. Rhodes Technologies
  155. Royal Melbourne Institute of Technology
  156. Saint Vincent Hospital
  157. Sandoz
  158. Santa Marta Golden Hemp
  159. Santé Cannabis
  160. Sanyal Biotechnology
  161. Sativa Group
  162. SciCann Therapeutics
  163. Serina Therapeutics
  164. Shoppers Drug Mart
  165. Sigma Analytical Services
  166. Solarvest BioEnergy
  167. South Carolina Research Foundation
  168. Spectrum Therapeutics
  169. Stellenbosch University
  170. STENOCARE
  171. STERO Biotechs
  172. Stevens Green
  173. Stony Brook University
  174. Syngene International
  175. Talent Biotechs
  176. Tassili Life Sciences
  177. Teewinot Life Sciences
  178. Tel Aviv Sourasky Medical Center
  179. Telethon Kids Institute
  180. Tetra Bio-Pharma
  181. T-G Initiatives
  182. THC Global Group
  183. The Hebrew University of Jerusalem
  184. 184.   The Ontario Lung   Association
  185. The Supreme Cannabis Company
  186. The University of Auckland
  187. The University of British Columbia
  188. The University of Mississippi
  189. The University of Seville
  190. The University of Western Australia
  191. The Valens
  192. Therapix Biosciences
  193. Thorne Research  
  194. Tilray
  195. True North Cannabis
  196. UC San Diego School of Medicine
  197. Universidad Complutense de Madrid
  198. University of Bordeaux
  199. University of Central Florida
  200. University of Guelph
  201. University of Toronto
  202. University of Washington
  203. Urban Cultivator
  204. Veritas Pharma
  205. Vitality Biopharma
  206. Vitiprints
  207. WeedMD
  208. Wisconsin Alumni Research Foundation
  209. World-Class Extractions
  210. Yale University
  211. Zelira Therapeutics
  212. Zenabis
  213. Zynerba Pharmaceuticals

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com